Clinical impact of multidrug-resistant organisms in liver cirrhosis: A retrospective cohort study in the intensive care setting

Table 3 Clinical outcomes stratified by multidrug-resistant organism colonization and infection status, n (%)/median (interquartile range)

Outcome	Colonized patients (n = 32)	Non-colonized (n = 75)	P value1	Infected patients (n = 91)	Non-infected (n = 16)	P value1
Mechanical ventilation	19 (59.4)	38 (50.7)	0.539	54 (59.3)	3 (18.8)	0.005a
Renal replacement therapy	13 (40.6)	23 (30.7)	0.438	31 (34.1)	5 (31.2)	1
Vasopressor use	18 (56.2)	34 (45.3)	0.41	49 (53.8)	3 (18.8)	0.013b
ICU LOS	10.0 (15.2)	8.0 (10.0)	0.513	9.0 (12.0)	5.0 (2.2)	0.003c
28-day transplant free survival	12 (37.5)	37 (49.3)	0.361	38 (41.8)	11 (68.8)	0.084
ICU survival	14 (43.8)	41 (54.7)	0.41	44 (48.4)	11 (68.8)	0.217
Hospital survival	10 (31.2)	35 (46.7)	0.206	34 (37.4)	11 (68.8)	0.038d
Hospital LOS (days)	27.0 (29.2)	21.0 (19.0)	0.083	24.0 (26.5)	14.0 (15.0)	0.03e

^aP < 0.01 for mechanical ventilation in infected vs non-infected patients.

^bP < 0.05 for vasopressor use in infected vs non-infected patients.

^cP < 0.01 for intensive care unit length of stay in infected vs non-infected patients.

^dP < 0.05 for hospital length of stay in infected vs non-infected patients.

^eP < 0.05 for hospital survival in infected vs non-infected patients.

¹P values were calculated using Fisher’s exact or Mann-Whitney U test, as appropriate.

LOS: Length of stay; ICU: Intensive care unit.